India's Molbio Diagnostics rises after Jefferies initiates with 'buy'
BUZZ-India's Molbio Diagnostics rises after Jefferies initiates with 'buy' ** Shares of Molbio Diagnostics MOLB.NS rise 2.5% to 1,287 rupees
** Jefferies initiates coverage of the diagnostic test maker with "buy" rating, and a PT of 1,600 rupees
** brokerage says MOLB "is among the few Indian innovation-led companies that have already demonstrated the success of its flagship platform with several others in pipeline to drive long-term growth"
** MOLB's Truenat - battery-operated molecular diagnostics platform - supports testing for 30 diseases and operates in an oligopolistic market - brokerage
** Truenat is lighter, faster, and less infrastructure-dependent than competitor Cepheid's GeneXpert, Jefferies says; adds, "with revenue of ~USD130m versus ~USD3bn scale, we believe Truenat is a transformative innovation with significant growth runway"
** Stock up 22.9% since trading debut on August 17
(Reporting by Puyaan Singh in Bengaluru)